Literature DB >> 21409527

Hepatocellular carcinoma: prevention and therapy.

Davendra P S Sohal1, Weijing Sun.   

Abstract

Hepatocellular carcinoma (HCC) is an aggressive malignancy of the liver and occurs most often in the setting of chronic liver disease. The most common acquired causes for this are chronic viral hepatitis infections (mostly HBV and HCV), and alcohol. Other causes include nonalcoholic fatty liver disease-related nonalcoholic steatohepatitis, autoimmune liver disease, and biliary diseases. In addition, certain heritable diseases like hemochromatosis and α-1-antitrypsin deficiency can also lead to HCC. Therefore, prevention of HCC can be achieved by preventing and controlling these problems. For treatment, curative modalities are surgical resection and liver transplantation. However, most patients are not candidates for these surgical maneuvers, and outcomes are poor. New therapeutic developments have brought some improvement with both local and systemic disease control.

Entities:  

Mesh:

Year:  2011        PMID: 21409527     DOI: 10.1007/s11912-011-0165-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  47 in total

Review 1.  Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview.

Authors:  Daniel Jaeck; Philippe Bachellier; Elie Oussoultzoglou; Jean-Christophe Weber; Philippe Wolf
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

Review 2.  Loco-regional treatment of hepatocellular carcinoma.

Authors:  Riccardo Lencioni
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

3.  A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.

Authors:  Wei-Ping Zhou; Eric C H Lai; Ai-Jun Li; Si-Yuan Fu; Jian-Ping Zhou; Ze-Ya Pan; Wan Yee Lau; Meng-Chao Wu
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

4.  Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial.

Authors:  E C Lai; C M Lo; S T Fan; C L Liu; J Wong
Journal:  Arch Surg       Date:  1998-02

5.  Management of hepatocellular carcinoma: from prevention to molecular targeted therapy.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

6.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Authors:  Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

7.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.

Authors:  Amani Asnacios; Laetitia Fartoux; Olivier Romano; Chloe Tesmoingt; Samy Louafi S; Touraj Mansoubakht; Pascal Artru; Thierry Poynard; Olivier Rosmorduc; Mohamed Hebbar; Julien Taieb
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more
  6 in total

1.  Socioeconomic status and hepatocellular carcinoma in the United States.

Authors:  Fatma M Shebl; David E Capo-Ramos; Barry I Graubard; Katherine A McGlynn; Sean F Altekruse
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-05       Impact factor: 4.254

Review 2.  Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.

Authors:  Gianni Testino; Paolo Borro
Journal:  World J Hepatol       Date:  2013-10-27

Review 3.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

Review 4.  Hepatocellular carcinoma: a review.

Authors:  Julius Balogh; David Victor; Emad H Asham; Sherilyn Gordon Burroughs; Maha Boktour; Ashish Saharia; Xian Li; R Mark Ghobrial; Howard P Monsour
Journal:  J Hepatocell Carcinoma       Date:  2016-10-05

5.  Circ_LDLR Knockdown Suppresses Progression of Hepatocellular Carcinoma via Modulating miR-7/RNF38 Axis.

Authors:  Yuming Jia; Shengchao Li; Meng Zhang; Zhilei Zhang; Chao Wang; Chong Zhang; Wuhan Yang; Li Peng; Zhuo Xu
Journal:  Cancer Manag Res       Date:  2021-01-13       Impact factor: 3.989

6.  Hepatocellular carcinoma: natural history, current management, and emerging tools.

Authors:  Christopher L Tinkle; Daphne Haas-Kogan
Journal:  Biologics       Date:  2012-07-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.